A clinical trial finds that the anticoagulant apixaban, which has been prescribed to help COVID-19 patients recover, is ineffective and in rare instances dangerous.
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Recent studies have lent support for a variety of hypotheses explaining the debilitating symptoms affecting millions of people after SARS-CoV-2 infection.
Launched with a $172 million philanthropic donation and funds from the state of Victoria, the Melbourne-based research institute aims to construct drug discovery platforms to speed the introduction of new therapies.
The Scientist’s Creative Services Team | 1 min read
Julie Lovchik will discuss how advanced flow cytometry instrumentation facilitates multiplex assessment of IgG, IgM, and IgA antibodies against SARS-CoV-2.
The immunizations are designed to target the latest Omicron subvariants, and are only authorized for people who have already received their primary vaccinations.